Gabelli Funds LLC decreased its position in shares of C R Bard Inc (NYSE:BCR) by 7.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 128,561 shares of the medical instruments supplier’s stock after selling 10,000 shares during the period. Gabelli Funds LLC’s holdings in C R Bard were worth $42,632,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in BCR. Cowen Inc. lifted its position in C R Bard by 100.7% during the 3rd quarter. Cowen Inc. now owns 571,487 shares of the medical instruments supplier’s stock worth $183,162,000 after acquiring an additional 286,685 shares during the last quarter. Nomura Holdings Inc. increased its holdings in shares of C R Bard by 2,381.1% during the 2nd quarter. Nomura Holdings Inc. now owns 288,572 shares of the medical instruments supplier’s stock worth $91,272,000 after purchasing an additional 276,941 shares during the period. Wells Fargo & Company MN increased its holdings in shares of C R Bard by 32.8% during the 3rd quarter. Wells Fargo & Company MN now owns 775,683 shares of the medical instruments supplier’s stock worth $248,607,000 after purchasing an additional 191,443 shares during the period. Nuance Investments LLC increased its holdings in shares of C R Bard by 47.6% during the 3rd quarter. Nuance Investments LLC now owns 479,686 shares of the medical instruments supplier’s stock worth $153,739,000 after purchasing an additional 154,650 shares during the period. Finally, BNP Paribas Arbitrage SA increased its holdings in shares of C R Bard by 75.8% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 353,485 shares of the medical instruments supplier’s stock worth $113,292,000 after purchasing an additional 152,468 shares during the period. 79.11% of the stock is owned by hedge funds and other institutional investors.

BCR has been the topic of several research reports. Zacks Investment Research upgraded shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price objective on the stock in a report on Tuesday, December 26th. ValuEngine downgraded shares of C R Bard from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Barclays boosted their price objective on shares of C R Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a report on Monday, November 6th. Cowen restated a “hold” rating and set a $317.00 price objective on shares of C R Bard in a report on Friday, November 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of C R Bard in a report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. C R Bard currently has a consensus rating of “Hold” and an average price target of $320.83.

In related news, insider Jim C. Beasley sold 15,044 shares of the company’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $332.00, for a total value of $4,994,608.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP John A. Deford sold 14,107 shares of the company’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $333.48, for a total transaction of $4,704,402.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,981 shares of company stock worth $21,970,370. Insiders own 0.80% of the company’s stock.

C R Bard Inc (NYSE BCR) opened at $331.24 on Monday. C R Bard Inc has a twelve month low of $222.42 and a twelve month high of $337.73. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57. The stock has a market cap of $24,140.00, a PE ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/c-r-bard-inc-bcr-shares-sold-by-gabelli-funds-llc/1845973.html.

C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C R Bard Inc (NYSE:BCR).

Institutional Ownership by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.